We describe a patient with refractory T-cell acute lymphoblastic leukemia who successfully underwent unmanipulated stem cell transplantation from an HLA 3-loci mismatched (haploidentical) sibling. In order to avoid severe graft-versus-host disease (GVHD), we used intensified GVHD prophylaxis consisting of tacrolimus, a short course of methotrexate, methylprednisolone, and mycophenolate mofetil. Hematopoietic reconstitution was rapid, with neutrophil count 45 Â 10 8 /l on day +16, and platelet count 42 Â 10 10 /l on day +25. There was no evidence of clinical acute GVHD. Bacterial, fungal, and viral infections were well controlled with antibiotics. The patient is still in complete remission past day +400. We suggest that unmanipulated HLA-mismatched transplantation with intensified GVHD prophylaxis is an alternative option for patients who do not have an HLA-identical donor.
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Allogeneic stem cell transplantation (SCT) remains the only curative treatment option for patients with advanced hematologic malignancies. In patients with chemoresistant relapse who do not have an HLA-identical related donor, a time-consuming search for a closely HLA-matched unrelated donor is not practical. Cord blood SCT, an alternative option, is not suitable for adult patients, since the number of nucleated cells infused is the most important factor in predicting transplant outcome. In such cases, SCT from an HLA-mismatched related donor has been carried out as another option. Recently, it was reported that HLA 3-loci mismatched (haploidentical) SCT had been performed using T-cell-depleted 1 and/or CD34-positive selected stem cells. 2 This method may overcome the barrier of HLA-mismatching, and may make it possible to use SCT to treat patients without an HLA-identical donor or patients who urgently need transplantation. However, a serious problem with SCT using T-cell-depleted bone marrow (BM) is an increased risk of life-threatening infection and relapse after transplantation.
2,3
In our study of 20 consecutive unrelated BMT recipients, including three cases of two allelic mismatched and nine cases of one allelic mismatched donors, none of the patients developed acute GVHD grades II-IV using a protocol of GVHD prophylaxis consisting of tacrolimus (FK506), a short course of methotrexate (MTX), and methylprednisolone (mPSL). 4 Therefore, we used unmanipulated HLA 3-loci mismatched (haploidentical) SCT to treat a patient with refractory T-cell acute lymphoblastic leukemia (T-ALL) urgently in need of SCT using GVHD prophylaxis based on a combined immunosuppressant regimen.
Case report
A 25-year-old male with a bulky mediastinal mass was admitted to another hospital in April 2000, and diagnosed with T-ALL (CD2
. He received treatment with the JALSG ALL-97 protocol, consisting of cyclophosphamide (CY), daunorubicin, vincristine (VCR), prednisone (PSL), and l-asparaginase (l-Asp), and achieved complete remission (CR) in July 2000, but relapsed in September 2000. A high dose of cytosine arabinoside (Ara-C), in addition to the combination of mitoxantrone, l-Asp, MTX, and mercaptopurine was administered as salvage chemotherapy, but leukemic cells remained in the BM, and soon regrew.
The patient was transferred to our hospital to receive an allogeneic SCT. His peripheral white blood cell count was 14 Â 10 9 /l (blasts 47%, neutrophils 38%, lymphocytes 2.5%), and the BM contained 88% lymphoblasts on admission. The mediastinal mass was reduced in size compared with the size at diagnosis, but was still present DRB1 1502, indicating that all of his family members had HLA 3-loci mismatches in both the graft-versus-host (GVH) and the host-versus-graft (HVG) directions. We decided to perform the SCT using his sister as donor. Written informed consent was obtained from the patient, his sister (donor), and his parents.
The clinical course is shown in Figure 2 . At first, in order to reduce the high leukemic burden, idarubicin (IDR) 12 mg/m 2 and Ara-C 2 g/m 2 were administered once on day À14. The conditioning regimen consisted of fludarabine (FLU) 30 mg/m 2 on days À10 to À6 (total dose 150 mg/m 2 ), Ara-C 2 g/m 2 on days À9 to À6 (total dose 8 g/m 2 ), CY 60 mg/kg on days À5 and À4 (total dose 120 mg/kg), and fractionated total body irradiation (TBI) (12 Gy in four fractions given twice daily on days À3 and À2). GVHD prophylaxis consisted of a continuous intravenous infusion of FK506 (the target blood concentration was 15-18 ng/ ml), a short course of MTX (10 mg/m 2 on day +1, 7 mg/m 2 on days +3, +6, and +11), mPSL 2 mg/kg in two doses daily from day +1, and oral mycophenolate mofetil (MMF) 15 mg/kg/day daily from day +5. The patient received marrow containing 3.6 Â 10 8 nucleated cells/kg (included 5.3 Â 10 6 CD34 + cells/kg). The graft was unmanipulated with the exception of red cell depletion. Granulocyte colony-stimulating factor (G-CSF, lenograstim) 300 mg/m 2 /day was given from day +5. This protocol was well tolerated. Hematopoietic reconstitution was rapid, with absolute neutrophil count 45 Â 10 8 /l on day +16, and platelet count 42 Â 10 10 /l on day +25. BM examination on day +20 demonstrated that he had achieved CR and complete donor chimerism based on both polymerase chain reaction-based analysis of a single variable number of tandem repeats (PCR-VNTR) and female-specific fluorescence in situ hybridization (FISH) analysis. Complete donor chimerism was also confirmed in the CD3 + cell, granulocyte, and monocyte fractions. The patient began to suffer from mild hypogastric pain on day +20. Fiberscopic and pathological examination revealed the presence of mild ischemic duodenitis, suggesting thrombotic microangiopathy, while viral infections including cytomegalovirus (CMV), Epstein-Barr virus, and human herpesvirus 6 were excluded based on virus-specific PCR analysis of biopsy samples. The symptoms disappeared as FK506 and mPSL were gradually tapered. After CMV antigenemia first appeared on day +41, he received ganciclovir (GCV) and foscarnet, and thereafter the CMV antigenemia resolved 2 weeks later. BM was examined biweekly to monitor for minimal residual disease (MRD) by a quantitation of Wilms' tumor gene (WT1) expression by reverse transcriptase-PCR, 5 and by CD45-blast gating flow cytometry, and to monitor donor-recipient chimerism by PCR-VNTR and female-specific FISH. All of these results demonstrated continued CR and complete donor chimerism. As shown in Figure 1 , a chest CT scan on day 74 revealed marked regression of the bulky mediastinal mass. MMF was discontinued on day +100. PSL and FK506 were tapered to 27.5 and 2 mg/day, respectively, without the development of GVHD on day +119, when the patient was discharged with 100% Karnofsky performance status. On day +400, when we submitted this case report, he was still in molecular remission with slight signs of chronic GVHD (mildly dry eyes and mouth, but with no skin lesion or liver dysfunction), which is well controlled by low dose immunosuppressants (FK506 0.4 mg/day and PSL 3 mg/ day).
Discussion
During the 1980s, transplantation of BM from family donors from other than a 1-antigen mismatched haploidentical donor was unsuccessful because of graft failure and severe GVHD. 6 Therefore, HLA 2-or more-loci mismatched SCT has been performed with T-cell depletion during the past decade, but the results have remained unsatisfactory. Recently, the Perugia group has reported that HLA 3-loci mismatched (haploidentical) SCT can be performed in combination with a 3-log T-cell depletion of the donor BM, a 7-to 10-fold increase in the dose of the transplant inoculum and an intensified preconditioning regimen.
2,7 According to their study, disease-free survival for ALL was reported to be about 17% at 2.5 years.
2
Although the use of a large number of T-cell depleted stem cells and/or an intensified preconditioning regimen over- comes graft rejection and GVHD attributed to the barrier of HLA-mismatching, expensive monoclonal antibodies, special apparatus for cell processing, 8 and manpower are required for depleting T cells from BM.
1-3, 7 We described a successful case of unmanipulated HLA 3-loci mismatched SCT. Instead of T-cell depletion, therefore, we attempted to control GVHD by the combined use of immunosuppressive drugs consisting of FK506, mPSL, MTX, and MMF. Hematopoietic engraftment was rapid, and unexpectedly, acute GVHD was not seen clinically. Fungal and viral infections were well controlled with appropriate antibiotics. The patient remains in molecular CR past day +400, although he was in chemoresistant relapse at the time of transplantation.
We consider that the four-drug regimen for GVHD prophylaxis we developed was very effective in controlling GVHD in this HLA 3-loci mismatched SCT. Furthermore, in this present case, feto-maternal immunological tolerance may have been involved in the absence of acute GVHD. The donor shared one paternal HLA-haplotype with the patient. A noninherited maternal antigen (NIMA) for the donor, HLA-A26, which the patient inherited from his mother, was detected in the donor peripheral blood by nested PCR analysis (data not shown). The potential role of feto-maternal microchimerism for immunological tolerance was first suggested in the case of renal transplantation, 9 but has never been established in hematopoietic SCT. Further investigations will be needed to confirm the significance of feto-maternal microchimerism.
Since the follow-up period is too short to prove clinical efficacy, we cannot yet speculate whether unmanipulated HLA 3-loci mismatched (haploidentical) SCT will become a regular treatment modality, but it might be one of the alternative options, especially in urgent situations. 
